Drug Reduces Graft-Versus-Host After Stem Cell Transplant

Chemokine receptor CCR5 antagonist maraviroc inhibits lymphocyte chemotaxis

THURSDAY, July 12 (HealthDay News) -- The chemokine receptor CCR5 antagonist maraviroc, which blocks lymphocyte trafficking, is safe and reduces the incidence of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem-cell transplantation, according to a phase I and II study published in the July 12 issue of the New England Journal of Medicine.

Ran Reshef, M.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the in vitro effect of maraviroc and its safety and efficacy when added to standard GVHD prophylaxis in 38 high-risk patients undergoing allogeneic hematopoietic stem-cell transplantation. Maraviroc was given orally twice a day, starting two days before transplantation until day 30.

The researchers found that, in vitro, maraviroc inhibited lymphocyte chemotaxis and CCR5 internalization, without impairing T-cell function or hematopoietic-cell colonies. The mean cumulative incidence rate of grade II to IV acute GVHD was 14.7 percent on day 100 and 23.6 percent at day 180 in 35 patients who could be evaluated. The mean cumulative incidence of grade III or IV GVHD was 5.9 percent at day 180, largely attributed to low rates of acute liver and gut GVHD which were absent before day 100. At one year the mean cumulative rate of death not preceded by disease relapse was 11.7 percent, and relapse and infection rates were not excessive.

"In this study, inhibition of lymphocyte trafficking was a specific and potentially effective new strategy to prevent visceral acute GVHD," Reshef and colleagues conclude.

The study was partially funded by Pfizer. Several authors disclosed receiving financial support from Pfizer and other pharmaceutical companies.

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events